Document Type : Original Article
Authors
1
Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Mansoura University.
2
Biochemistry and Molecular Biology Department, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt
3
Biotechnology and Life Sciences Department, Faculty of Postgraduate Studies for Advanced Sciences, Beni-Suef University, Beni-Suef.
4
Biochemistry and Molecular Biology Department, Faculty of Veterinary Medicine, Mansoura University.
Abstract
Globalization and urbanization have significantly altered human eating habits, leading to an increased preference for high-caloric fast foods. This shift, particularly the high consumption of high-fat diets and fructose-sweetened beverages, has contributed to the rising prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide. Despite this, treatment options for NAFLD remain limited, with current pharmacological treatments associated with adverse side effects. Previous research has highlighted the potential of flavonoids—natural, non-toxic compounds—with significant antioxidant, anti-inflammatory, and metabolic disease-modulating effects that could help alleviate NAFLD. Recently, the use of flavonoids for modifying nanomaterial surfaces has gained attention due to their combined benefits. In this study, chrysin (Chr), a bioactive flavonoid, was used as a reducing agent to synthesize chrysin-reduced graphene oxide (Chr-RGO) nanosheets. The incorporation of Chr onto graphene oxide (GO) was confirmed through electron microscopy (TEM) and zeta potential measurements. The results suggest that Chr-RGO demonstrates significantly enhanced efficacy compared to crude Chr in reducing steatosis, inflammation, oxidative stress, and hyperglycemia. Chr-RGO shows promise as a novel and effective treatment for NAFLD induced by a high-fat, high-fructose diet (HFFD).
Keywords
Main Subjects
)
View on SCiNiTO